This has resulted in a precise classification, such as the identification of ALK1 gene rearrangements in the inflammatory myofibroblastic tumours (IMTs), SMARCA4 deficiency in SMARCA4 deficient uterus sarcomas and rearrangements of ESR1 or GREB1 genes in uterine tumours resembling ovarian sex cord tumours. This evidence concerns the gene SMARCA4 and uterine corpus sarcoma.